HH160 / Huahui Health - LARVOL DELTA

A symmetrical hexavalent trispecific antibody, HH160, targeting PD-1, CTLA-4 and VEGF-A for enhanced anti-cancer effects (AACR 2025) - "Background: Antiangiogenic agents, such as the anti-vascular endothelial growth factor A (VEGF-A) antibody Bevacizumab, are among the first targeted therapies in cancer treatment. Our study demonstrates that HH160 is a promising trispecific antibody for simultaneously targeting PD-1, CTLA4 and VEGF-A. It has the potential to harness the synergistic anti-tumor mechanisms, overcome resistance to monotherapy, and simplify the dosing regimen, supporting further development and clinical investigation."

Trispecific • Cervical Cancer • Liver Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • IFNG • IL2